Melisa Zişan KARSLIOĞLU, Melek Banu HOŞAL, Oya TEKELİ

Periocular changes in topical bimatoprost and latanoprost use

Background/aim: To evaluate the periocular changes due to topical bimatoprost and latanoprost use and to investigate their effects on the lacrimal drainage system. Materials and methods: All participants (69 eyes of 43 patients, 52 eyes of 26 controls) were classified into three groups: bimatoprost (0.03%) users, latanoprost (0.005%) users, and healthy controls. Each patient was examined before prostaglandin therapy, and then at the first, third, sixth, and twelfth month of therapy. Palpebral fissure height, upper eyelid crease, and levator function were measured, and lacrimal system drainage irrigation was performed. Periocular hyperpigmentation and upper eyelid sulcus were also examined. Results: No significant change was identified in palpebral fissure height or levator function in any group. However, in upper eyelid crease, among bimatoprost users, a statistically significant increase was observed when compared to the control group (P < 0.001). Patients with skin type II and III, in bimatoprost users, and patients with skin type III, in latanoprost users, had statistically significant hyperpigmentation (P < 0.001) after the third month of therapy. During follow-up, no lacrimal drainage system obstruction was seen. Conclusion: Topical bimatoprost therapy causes more periocular changes than latanoprost therapy. Thus, in unilateral cases, patients should be well informed about these probable changes before therapy.

Anahtar Kelimeler:

Bimatoprost, eyelids, lacrimal drainage, latanoprost

Periocular changes in topical bimatoprost and latanoprost use

Keywords:

Bimatoprost, eyelids, lacrimal drainage, latanoprost,

PDF

___

European Glaucoma Society. Treatment principles and options. In: Terminology and Guidelines for Glaucoma, Third edition. Savona, Italy: Editrice Dogma; 2008. pp. 136–138. 2. Astin M, Stjernschantz J, Selen G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res 1994; 59: 401– 407.
Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996; 9: 363–378.
Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997; 41(Suppl 2): S129–138.
Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost- induced periocular skin pigmentation: histopathological study. Arch Ophthalmol 2005; 123: 1541–1546.
Patil AJ, Vajaranant TS, Edward DP. Bimatoprost – a review. Expert Opin Pharmacother 2009; 10: 2759–2768.
Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM; Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001; 18: 110–121.
Burnett JW, Harvey VM. Circumscribed palmar or plantar hypokeratosis: report of two additional cases. J Am Acad Dermatol 2004; 51: 843–844.
O’Toole L, Cahill M, O’Brien C. Eyelid hypertrichosis associated with latanoprost is reversible. Eur J Ophthalmol 2001; 11: 377–379.
Modschiedler K, von den Driesch P, Paus R. Hyperpigmentosis and hypertrichosis of the eyelids after use of bimatoprost eye drops. J Dtsch Dermatol Ges 2005; 3: 276–277.
Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost-induced periocular skin changes in Caucasians. Ophthalmology 2006; 113: 1961–1967.
Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001; 119: 614–615.
Chen CS, Wells J, Craig JE. Topical prostaglandin F2a analog induced poliosis. Am J Ophthalmol 2004; 137: 965–966.
Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy – an unfamiliar side effect of prostaglandin analogues. Orbit 2010; 29: 357–359.
Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 2011; 55: 22–27.
Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 2008; 24: 302–307.
Fitzpatrick TB. The validity and practicality of sun-reactive skin type I through VI. Arc Dermatol 1988; 124: 869–871.
Woodward DF, Krauss AH, Chen J, Liang Y, Li C, Protzman CE, Bogardus A, Chen R, Kedzie KM, Krauss HA et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003; 305: 772–785.
Peplinski S, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004; 81: 574–577.
Tan J, Berke S. Latanoprost-induced prostaglandin-associated periorbitopathy. Optom Vis Sci 2013; 90: e245–247.
Altieri M, Ferrari E. Do prostaglandin analogs affect eyelid position and motility? J Ocul Pharmacol Ther 2011; 27: 511– 517.
Wang PX, Koh VT, Cheng JF. Periorbital muscle atrophy associated with topical bimatoprost therapy. Clin Ophthalmol 2014; 8: 311–314.
Abdel-Malek ZA, Swope VB, Amornsiripanitch N, Nordlund JJ. In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins. Cancer Res 1987; 47: 3141–3146.
Imesch PD, Wallow IH, Albert DM. The color of the human eye. A review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol 1997; 41(Suppl 2): S117–123.
Jimbow K. Formation, chemical compositions and functions of melanin pigments in mammals. In: Matoltsy AG, editor. Biology of the Integument. New York, NY, USA: Springer Verlag 1986. p. 278.
Artunay Ö, Yüzbaşıoğlu E, Şengül A, Rasier R, Bahçecioğlu H. Antiglokomatöz ilaç kullanımı ile nazolakrimal kanal tıkanıklığı ilişkisi. Turkiye Klinikleri J Ophthalmol 2010; 19: 150–115 (in Turkish).